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Background: Uncertainty still surrounds the association between metabolic syndrome (MetS) and depression. We
aimed to evaluate the association between MetS and elevated depressive symptoms in a general Japanese
population.
Methods: This is a cross-sectional survey of 3,113 community-dwelling individuals aged 40 years or over. MetS was
defined according to the joint interim statement. MetS was diagnosed when a subject had three or more of the
following components: 1) central obesity (waist circumference ≥90 cm for men, ≥80 cm in for women); 2) elevated
blood pressure (≥130/85 mmHg or current use of antihypertensive medication); 3) hypertriglyceridemia
(≥1.7 mmol/L); 4) low HDL cholesterol (< 1.0 mmol/L for men, < 1.3 mmol/L for women); and 5) elevated fasting
plasma glucose (≥5.55 mmol/L or current use of antidiabetic medication). Depressive symptoms were assessed
using the Center for Epidemiologic Studies Depression Scale (CES-D). The age- and multivariable-adjusted odds
ratio (OR) and 95% confidence interval (CI) were estimated using a logistic regression model.
Results: Elevated depressive symptoms were observed in 4.3% of male and 6.3% of female participants. In men, the
age-adjusted prevalence of elevated depressive symptoms was significantly higher in subjects with MetS than in
those without (7.1% versus 3.6%, p = 0.04). The prevalence of elevated depressive symptoms rose progressively as
the number of MetS components increased (3.5%, 3.6%, 5.8%, and 9.2% in male subjects with 0–1, 2, 3, and ≥4
components, respectively; p = 0.02 for trend). This association remained significant even after adjustment for age,
marital status, history of cardiovascular disease, smoking habit, alcohol intake, and regular exercise. In women, on
the other hand, there was no clear association between MetS and depressive symptoms.
Conclusions: MetS was associated with elevated depressive symptoms in a general population of Japanese men.
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Depression is an important cause of long-term disability
and dependency and is responsible for 11.8% of years-
lived-with-disability [1,2]. Effective prevention of the
burdens associated with depression will require a strat-
egy based on better knowledge of its risk factors.* Correspondence: harima@envmed.med.kyushu-u.ac.jp
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reproduction in any medium, provided the orRecently, a systematic review of observational studies
demonstrated a link between metabolic syndrome
(MetS) and depressive symptoms [3]. However, current
knowledge of the association between MetS and depres-
sive symptoms was derived mainly from studies
conducted in Western populations; so it is unclear to
what extent these findings apply to Asian populations.
The present cross-sectional study evaluates the associ-
ation of MetS with depressive symptoms in a general
population of Japanese.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Study population and design
The Hisayama Study is a prospective cohort study of
cerebro-cardiovascular diseases in a suburban commu-
nity, the town of Hisayama, adjacent to of the city of
Fukuoka, Japan [4-6]. Based on data from the national
census, the age and occupational distributions in
Hisayama have been almost identical to those in Japan
as a whole since the 1960s [4]. As a part of this study, all
4330 residents of the town of Hisayama aged 40 years or
older were invited to participate in a cross-sectional
examination in 2007 and 2008. Among them, 3,376 resi-
dents consented to participate (participation rate 78.0%).
After the exclusion of 263 subjects with missing data on
depression or MetS, a total of 3,113 subjects were in-
cluded in the present analysis.
Metabolic syndrome
Information on current use of antihypertensive and anti-
diabetic medications was collected using a self-adminis-
tered questionnaire and confirmed using the consumer
drug information by trained staff. Blood pressure was
measured three times after the subject had rested for at
least 5 minutes prior to each measurement using a semi-
automatic device (BP-203 RVIIIB; Omron Healthcare)
based on the cuff-oscillometric principle with the subject
in the sitting position. The mean of the three measure-
ments was used for the analysis. Waist circumference was
measured at the umbilical level in a standing position by a
trained staff member. Blood samples were collected from
an antecubital vein after an overnight fast for the deter-
mination of serum lipids and plasma glucose levels. Serum
total cholesterol, triglyceride, and high-density lipoprotein
(HDL) cholesterol concentrations were determined enzy-
matically. Fasting blood glucose levels were measured by
the glucose oxidase method. MetS was defined based on
the joint interim statement of the International Diabetes
Federation Task Force on Epidemiology and Prevention;
National Heart, Lung, and Blood Institute; American
Heart Association; World Heart Federation; International
Atherosclerosis Society; and International Association for
the Study of Obesity [7]. MetS was diagnosed when a sub-
ject had three or more of the following components: 1)
central obesity (waist circumference ≥90 cm for men,
≥80 cm for women); 2) elevated blood pressure (≥130/
85 mmHg or current use of antihypertensive medication);
3) hypertriglyceridemia (≥1.7 mmol/L); 4) low HDL chol-
esterol (< 1.0 mmol/L for men, < 1.3 mmol/L for women);
and 5) elevated fasting plasma glucose (≥5.55 mmol/L or
current use of antidiabetic medication).
Other covariates
Each participant completed a self-administered question-
naire covering marital status, medical history, smokinghabit, alcohol intake, and exercise. The questionnaire was
checked by trained interviewers. Marital status was classi-
fied as either having a spouse on a family register or not
(e.g. single, divorced). A history of cardiovascular disease
was defined as prior stroke (ICD10 codes I60, I61, I63 and
I64) or coronary heart disease (I20 – I25) with or without
coronary revascularization (coronary intervention or by-
pass surgery). A smoking habit was defined as current
habitual smoking of 1 or more cigarettes per day. Alcohol
intake was defined as current habitual drinking of at least
once per month. Subjects who engaged in sports or other
forms of exercise ≥3 times a week during their leisure time
made up a regular exercise group.
Elevated depressive symptoms
Depressive symptoms were assessed using the Japanese,
20-item version of the Center for Epidemiologic Studies
Depression Scale (CES-D) [8,9], the reliability of which
has been validated [10]. Elevated depressive symptoms
were defined as a CES-D score of ≥16 or current use of
antidepressant medication defined based on the self-
administered questionnaire and the consumer drug
information.
Statistical analyses
In the present analysis, the key risk factor was MetS and
its components, and the outcome was elevated depres-
sive symptoms. All analyses were conducted separately
for men and women. The prevalence of elevated depres-
sive symptoms in each subgroup defined by MetS or its
components was standardized for age distribution of the
total study subjects by the direct method using 10-year
age groupings. The association between components of
Mets and elevated depressive symptoms was evaluated
using an age-adjusted logistic regression model. The as-
sociation of Mets and the number of its components
with elevated depressive symptoms was evaluated using
age- and multivariable-adjusted logistic regression
models. The multivariable-adjusted models included age,
marital status, history of cardiovascular disease, smoking
habit, alcohol intake, and regular exercise as covariates.
The differences in the association of MetS and the
number of its components with elevated depressive
symptoms between men and women were evaluated by
adding interaction term(s) to the logistic regression
models. P < 0.05 was considered statistically significant
in all analyses. The SAS software package, version 9.2
(SAS Institute) was used for statistical analysis.
Ethical considerations
The study protocol was approved by Kyushu University
Institutional Review Board for Clinical Research, and the
procedures followed were in accordance with national
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Results
The baseline characteristics of subjects with and without
MetS are shown by sex in Table 1. Subjects with MetS
had higher values for waist circumference, systolic and
diastolic blood pressures, serum total cholesterol, triglyc-
erides and fasting plasma glucose; they also had lower
levels of HDL cholesterol in both men and women. The
frequencies of antihypertensive and antidiabetic medica-
tions were also higher in MetS subjects of both sexes.
Women with MetS were older and less likely to be alcohol
drinkers.
Elevated depressive symptoms were observed in 58
(4.3%) men and 111 (6.3%) women. Table 2 shows the
age-adjusted prevalence and odds ratio [OR] for elevated
depressive symptoms according to the presence of MetS
components in men and women. The age-adjusted
prevalence of elevated depressive symptoms was higher
in men with low HDL cholesterol (age-adjusted OR 2.55
[95% CI 1.11-5.86]) and men with elevated fasting
plasma glucose (1.90 [95% CI 1.06-3.42]). These associa-
tions remained significant even after controlling for age,
marital status, history of cardiovascular disease, smoking
habit, alcohol intake, and regular exercise (low HDL
cholesterol: multivariable-adjusted OR 2.44 [95% CI
1.04-5.69], elevated fasting plasma glucose: 1.93 [95% CI
1.07-3.49]). In women, on the other hand, there were noTable 1 Characteristics of men and women with and without
Men
MetS (−) MetS (+)
(n = 965) (n = 388)
Age (years) 63 ± 12 62 ± 10
Single or divorced (%) 11.7 11.6
History of cardiovascular disease (%) 8.4 10.6
Antihypertensive medication (%) 28.2 44.6
Antidiabetic medication (%) 7.2 17.0
Waist circumference (cm) 83.5 ± 7.2 92.6 ± 6.8
Systolic blood pressure (mmHg) 129 ± 17 144 ± 15
Diastolic blood pressure (mmHg) 79 ± 9 88 ± 9
Total cholesterol (mmol/L) 5.10 ± 0.87 5.34 ± 0.93
Triglycerides (mmol/L) 1.10(0.82–1.47) 2.02(1.47–2.84
HDL cholesterol (mmol/L) 1.65 ± 0.42 1.39 ± 0.37
Fasting plasma glucose (mmol/L) 5.8 ± 1.2 6.7 ± 1.6
Smoking habit (%) 33.6 38.0
Alcohol intake (%) 68.0 71.4
Regular exercise (%) 13.7 12.9
MetS metabolic syndrome; HDL high-density lipoprotein.
Values are mean ± SD, median (interquartile range) or frequency.
The differences between subjects with and without MetS were tested by Wilcoxonclear associations between MetS components and depressive
symptoms (all p > 0.05).
Table 3 shows the association of MetS with depressive
symptoms in men and women. The age-adjusted preva-
lence of elevated depressive symptoms was significantly
higher in men with MetS than in those without it (7.1%
versus 3.6%; age-adjusted OR 1.78 [95% CI 1.03-3.08]).
This association remained significant even after control-
ling for age, marital status, history of cardiovascular dis-
ease, smoking habit, alcohol intake, and regular exercise
(multivariable-adjusted OR 1.82 [95% CI 1.05-3.15]). In
women, on the other hand, there were no significant
associations between MetS and depressive symptoms
(p = 0.10; p = 0.006 for homogeneity between men and
women).
The age-adjusted prevalence and adjusted OR for ele-
vated depressive symptoms according to the number of
MetS components are shown by sex in Table 4. In men,
the age-adjusted prevalence rose with the number of
MetS components: it was 3.5%, 3.6%, 5.8%, and 9.2% for
subjects with 0–1, 2, 3, and ≥4 components, respectively
(p = 0.02 for trend). A significant association was ob-
served even after controlling for the aforementioned
confounding factors (p = 0.01 for trend). When the
number of MetS was used as a continuous variable, an
increase in 1 component was associated with a 35%
(95% CI 8-67%) increase in elevated depressive symp-
toms. In contrast to men, women showed no clear asso-
ciations between the number of MetS components andmetabolic syndrome
Women
P value MetS (−) MetS (+) P value
(n = 1261) (n = 499)
0.14 62 ± 13 67 ± 11 < 0.0001
0.95 27.5 31.9 0.07
0.21 2.6 4.8 0.02
< 0.0001 23.2 50.1 < 0.0001
< 0.0001 1.8 17.6 < 0.0001
< 0.0001 81.3 ± 9.3 91.4 ± 9.3 < 0.0001
< 0.0001 125 ± 18 144 ± 16 < 0.0001
< 0.0001 75 ± 10 84 ± 10 < 0.0001
0.0001 5.57 ± 0.89 5.73 ± 0.93 0.0008
) < 0.0001 0.93(0.69–1.23) 1.57(1.09–2.04) < 0.0001
< 0.0001 1.95 ± 0.43 1.61 ± 0.42 < 0.0001
< 0.0001 5.3 ± 0.7 6.4 ± 1.5 < 0.0001
0.12 7.6 7.3 0.82
0.22 33.7 26.7 0.004
0.70 10.1 12.6 0.12
tests for continuous variables and chi-square tests for categorical variables.
Table 2 Components of metabolic syndrome and










No 34/912 3.6 Reference
Yes 24/441 5.9 1.61 (0.94–2.77) 0.08
Elevated BP
No 21/582 3.9 Reference
Yes 37/771 4.9 1.26 (0.73–2.18) 0.41
Hypertriglyceridemia
No 40/939 4.1 Reference
Yes 18/414 4.8 1.17 (0.66–2.09) 0.60
Low HDL cholesterol
No 51/1276 4.0 Reference
Yes 7/77 8.3 2.55 (1.11–5.86) 0.03
Elevated FPG
No 16/570 2.9 Reference
Yes 42/783 5.5 1.90 (1.06–3.42) 0.03
Women
Central obesity
No 43/593 7.4 Reference
Yes 68/1167 5.9 0.78 (0.53–1.16) 0.22
Elevated BP
No 58/899 6.8 Reference
Yes 53/861 6.2 0.91 (0.61–1.36) 0.65
Hypertriglyceridemia
No 100/1471 6.8 Reference
Yes 11/289 3.6 0.54 (0.28–1.01) 0.05
Low HDL cholesterol
No 102/1607 6.3 Reference
Yes 9/153 6.4 0.92 (0.45–1.85) 0.81
Elevated FPG
No 71/1103 6.5 Reference
Yes 40/657 6.3 0.93 (0.62–1.39) 0.71
OR odds ratio, 95% CI 95% confidence interval, BP blood pressure, HDL high-
density lipoprotein, FPG fasting plasma glucose.
OR and P values were estimated using logistic regression models.
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0.76-1.06) per 1 component increase; p = 0.04 for homo-
geneity between men and women).
Discussion
The present cross-sectional examination of a general
population of Japanese demonstrated a higher prevalence
of elevated depressive symptoms in male subjects with
MetS compared to those without it. This associationremained significant even after controlling for the effects
of age, marital status, history of cardiovascular disease,
smoking habit, alcohol intake, and regular exercise. Fur-
thermore, the prevalence of elevated depressive symptoms
rose with the number of MetS components. In female
subjects, on the other hand, there was no clear association
between MetS and depressive symptoms.
Although a number of observational studies have in-
vestigated the association between MetS and depressive
symptoms, their conclusions have been inconsistent
[11-29]. With regard to cross-sectional studies, a French
study demonstrated elevated depressive symptoms in
men and women with MetS [14]. The PPP-Bonita Study
also showed close associations of MetS and its compo-
nents with depressive symptoms in Finnish men and
women [29]. With respect to longitudinal design re-
search, the Whitehall II study demonstrated that the
presence of MetS was associated with 38% increased
risks of future depressive symptoms in men and women
in London [16]. The Health in Men Study showed that
MetS was a strong predictor of the future development
of depression in elderly Australian men [17]. A positive
association between MetS and the incidence of depres-
sion was also reported in an office-based study of 956
Japanese men [18]. On the other hand, a cohort study
from France demonstrated no significant association be-
tween MetS and depressive symptoms in elderly subjects
aged about 70–90 years old [24]. A recent systematic
review and a meta analysis including all these studies,
however, demonstrated a clear relationship between MetS
and depression. Our findings from the Hisayama Study
suggest that the concept of a link between MetS and
depression is likely to be applicable to Japanese men.
Several population-based observational studies have
reported the association between MetS and depression
separately for men and women. A cross-sectional study
in France demonstrated that depression and depressive
symptoms were associated with MetS, irrespective of
gender [14]. A cross-sectional study in Poland showed
that MetS was observed more frequently among male
subjects with depressive symptoms than those without,
while there were no associations among women [12]. A
cross-sectional study in the United States reported that
women with a history of major depressive episode were
twice as likely to have metabolic syndrome compared
with those without such a history, but men with history
of depression were not significantly more likely to have
MetS [11]. A cohort study in Finland found that MetS
was not associated with depression or anxiety in either
men or women [13]. Therefore, there has been signifi-
cant inconsistency in gender differences in the link
between MetS and depression in Western populations.
With regard to Asian populations, on the other hand, a
cohort study of Japanese male employees showed a
Table 3 Metabolic syndrome and elevated depressive symptoms in men and women
N of cases/participants Age-adjusted Multivariable-adjusted*
Prevalence (%) OR (95% CI) P value OR (95% CI) P value
Men
MetS (−) 35/965 3.6 Reference Reference
MetS (+) 23/388 7.1 1.78 (1.03–3.08) 0.04 1.82 (1.05–3.15) 0.03
Women
MetS (−) 87/1261 7.0 Reference Reference
MetS (+) 24/499 5.2 0.66 (0.41–1.06) 0.08 0.67 (0.42–1.08) 0.10
MetS metabolic syndrome, OR odds ratio, 95% CI 95% confidence interval.
OR and P values were estimated using logistic regression models.
*Adjusted for age, marital status, history of cardiovascular disease, smoking habit, alcohol intake and regular exercise.
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cross-sectional study of Japanese subjects in Takarazuka
City demonstrated that the mean depression score was
higher for men with MetS than those without it, while de-
pression was not associated with MetS in women [25]. In
the present study of Japanese subjects, MetS was associ-
ated with elevated depressive symptoms in men but not in
women. In Asian populations, MetS may be associated
with depressive symptoms only in men.
One of the mechanisms underlying the association
between MetS and depressive symptoms is thought to
be the stress-induced hyperactivity of the hypothalamic-
pituitary-adrenal (HPA) axis, which is common in de-
pression [30-32] and could lead to metabolic alterations
[33-35]. Chronic stress has also been shown to increase
the risk of metabolic disorders through elevated sympa-
thetic activity [36]. Another potential mechanism is that
cerebral small vessel disease associated with MetS [37]
can increase the risk of late-life depression [38,39]. It is
also possible that behavioral factors associated with de-
pressive symptoms, such as physical inactivity and poorTable 4 The number of metabolic syndrome components and
N of cases/participants











MetS metabolic syndrome, OR odds ratio, 95% CI 95% confidence interval.
OR and P values were estimated using logistic regression models.
*Adjusted for age, marital status, history of cardiovascular disease, smoking habit, adiet, contribute to central adiposity and metabolic
disorders.
Another important finding from the present analysis is
the lack of associations between MetS and depressive
symptoms in women. This finding is consistent with a
previous cross-sectional study. The SOPKARD project
demonstrated clear associations between MetS and de-
pressive symptoms in Polish men but not in Polish
women [12]. The reason for this discrepancy has not
been clearly resolved, but it may be attributable to het-
erogeneity in genetic factors, hormonal factors, socio-
economic factors and social roles between men and
women.
There were several limitations to this study. Because
of the cross-sectional nature of the study, we were
unable to determine whether or not there was a causal
association between MetS and the development of de-
pressive symptoms. In addition, we were unable to ad-
dress the potential mechanisms underlying the reported
associations, the self-reported covariates had somewhat
limited accuracy, and the study lacked definite diagnosiselevated depressive symptoms in men and women
Age-adjusted Multivariable-adjusted*
e (%) OR (95% CI) P trend OR (95% CI) P trend
Reference Reference
0.80 (0.44–1.45) 0.84 (0.46–1.55)
1.17 (0.61–2.25) 1.20 (0.62–2.31)
2.43 (1.22–4.86) 0.02 2.47 (1.22–4.96) 0.01
Reference Reference
1.03 (0.67–1.58) 1.05 (0.68–1.62)
0.58 (0.33–1.01) 0.56 (0.32–0.99)
1.01 (0.50–2.06) 0.12 1.10 (0.54–2.25) 0.17
lcohol intake and regular exercise.
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chiatrists using standard criteria.
Conclusions
In conclusion, MetS was associated with elevated de-
pressive symptoms in a general population of Japanese
men. Screening of depressive symptoms in men with
MetS is likely to aid in the early detection and treatment
of depression, and might be able to provide additional
protection against the enormous burden of mental disor-
ders in Japan.
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